Alcobra prices upsized IPO at $8, below the range

By
A A A

Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised $25 million by offering 3.1 million shares at $8. The company had planned to offer 2.3 million shares at $10 to $12; total proceeds were $25 million, as expected. Alcobra plans to list on the NASDAQ under the symbol ADHD. Aegis Capital acted as the sole bookrunner on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ADHD

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Avatars of the Luxe Life
Avatars of the Luxe Life            

Stocks

Referenced

Most Active by Volume

77,558,232
  • $6.745 ▲ 11.30%
56,875,952
  • $17.44 ▲ 1.04%
53,554,524
  • $6.85 ▲ 2.24%
47,439,615
  • $7.79 ▲ 1.96%
43,423,804
  • $111.9866 ▲ 2.35%
38,864,114
  • $45.08 ▲ 9.52%
38,149,839
  • $7.15 ▲ 1.85%
37,345,215
  • $103.861 ▲ 2.02%
As of 12/18/2014, 03:19 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com